|
Patent landscape, scope, and claims: |
United States Patent 7,070,808 Landscape: Scope, Claim Boundaries, and US Exclusivity/IP Risk for Acrylic Therapeutic Adhesives with Highly Plasticizing Drugs
Bottom line: US Patent 7,070,808 claims a specific acrylic pressure-sensitive/adhesive polymer architecture plus a defined crosslinking system and a quantified loading of a “highly plasticizing drug” (including selegiline and other listed drugs). The claim scope is narrow in polymer composition ranges but broad in drug identity (within the enumerated list) and in crosslinking agent “class” (by name to listed agents). Freedom-to-operate (FTO) hinges on whether a formulation matches the polymer ratios, crosslinking functional monomer, and drug loading window.
What patents protect therapeutic adhesive formulations with selegiline or fluoxetine as highly plasticizing drugs?
Direct protection (US 7,070,808): The patent protects an adhesive mixture where a highly plasticizing drug is incorporated into an acrylic polymer adhesive matrix that is crosslinked.
Core structural claim elements (Claim 1 skeleton)
Claim 1 (therapeutic adhesive formulation) requires all of the following:
- Acrylic polymeric adhesive fraction: 65% to 97% by weight
- Within that adhesive fraction, the polymer includes:
- C4–C12 alkyl acrylate: 40% to 90%
- C1–C4 alkyl acrylate hardening monomer: 10% to 40%
- Functionalizing monomer for crosslinking: 1% to 20%
- Crosslinking agent (not quantified in Claim 1; quantified in dependent claims)
- Highly plasticizing drug: 3% to 35% by weight of the total mixture
Drug identity is limited to the enumerated “highly plasticizing drug” list in dependent claim 8. Claim 1 itself uses the term “highly plasticizing drug” without naming, but later claims cabin the allowed drugs.
Included “highly plasticizing drugs” (dependent Claim 8)
- selegiline
- fluoxetine
- Des-methyl selegiline
- tetracaine
- chlorpheniramine
Further narrow: selegiline (Claim 9).
Formulation composition boundaries
- C4–C12 alkyl acrylate: 40–90% within acrylic adhesive
- Hardening monomer (C1–C4): 10–40% within acrylic adhesive
- Functionalizing/crosslinking monomer: 1–20%
- Highly plasticizing drug loading: 3–35%
- Crosslinker selection and amount: selection in Claim 12; amount window in Claim 13.
How broad are US 7,070,808 claims in drug type, polymer chemistry, and crosslinker choice?
Featured-snippet answer: The claims are broad on drug selection only within a fixed list, but narrow on the polymer blend ranges and crosslinking chemistry.
Drug scope
- Claim 1 uses a defined functional characterization: “highly plasticizing drug.”
- Claim 8 enumerates the specific drugs.
- Claim 9 narrows to selegiline.
Implication: If a product uses a different drug not in the Claim 8 list, there is a strong argument it falls outside the explicit dependent-claim drug scope. However, the open term “highly plasticizing drug” in Claim 1 can still create an argument that other drugs qualify if they behave as “highly plasticizing,” depending on how a court construes that phrase.
Polymer architecture scope
The combination of:
- Longer-chain alkyl acrylate (C4–C12) for softness/plasticization compatibility, and
- short-chain alkyl acrylate hardening monomers (C1–C4) for tack/strength balance, and
- crosslinkable functional monomers (1–20%),
creates a tight claim on the polymer recipe.
Crosslinking agent scope
Claim 12 lists crosslinking agents, including:
- butyl titinate
- polybutyl titinate
- aluminum isopropoxide
- aluminum zinc acetate
- multivalent metals
- methylol ureas
- melamines
Claim 13 sets a crosslinker amount range: 0.005% to 2.0% of the adhesive.
Implication: Products using a materially different crosslinking agent (outside the listed species/class) reduce infringement risk, unless “multivalent metals” and claim construction capture the alternative crosslinker.
What is the claim-by-claim scope of US 7,070,808 (elements, ranges, and limiting features)?
Independent claim: Claim 1
Requires all:
- Acrylic polymeric adhesive fraction: 65–97%
- C4–C12 alkyl acrylate: 40–90% (within adhesive polymer)
- C1–C4 alkyl acrylate hardening monomer: 10–40% (within adhesive polymer)
- Crosslinking functional monomer: 1–20%
- Crosslinking agent: present (identity not limited in Claim 1)
- Highly plasticizing drug: 3–35% by weight of total formulation
Dependent claims that materially narrow scope
| Claim |
Added limitation(s) |
Scope impact |
| 2 |
C4–C12 alkyl acrylate is one of: 2-ethylhexyl acrylate, butyl acrylate, n-decyl, n-nonyl, 2-ethyoctyl, isooctyl, dodecyl-acrylate |
Locks the C4–C12 selection to enumerated monomers |
| 3 |
C4–C12 alkyl acrylate in adhesive: 60–80% |
Narrows the alkyl acrylate portion to a tighter band |
| 4 |
Hardening monomer is one of: methyl acrylate, methyl methacrylate, ethyl acrylate, ethyl methacrylate, hydroxyethyl acrylate, hydroxy propyl methacrylate |
Locks the hardening monomer identity |
| 5 |
Hardening monomer in adhesive: 15–30% |
Narrows the hardener window |
| 6 |
Functionalizing monomer is one of: acrylic acid, hydroxyethyl acrylate, methacrylic acid, acrylamide |
Locks crosslinkable functionality |
| 7 |
Functionalizing monomer amount: 3–8% |
Narrows crosslink functionality fraction |
| 8 |
Highly plasticizing drug is one of: selegiline, fluoxetine, des-methyl selegiline, tetracaine, chlorpheniramine |
Narrows drug identity explicitly |
| 9 |
Drug is selegiline |
Narrows drug further |
| 10 |
Highly plasticizing drug loading: 3–25% |
Narrows drug loading band |
| 11 |
Drug loading: 3–18% |
Tightens further |
| 12 |
Crosslinking agent selected from list including titinates, aluminum salts, multivalent metals, methylol ureas, melamines |
Constrains crosslinker identity/class |
| 13 |
Crosslinking agent amount: 0.005–2.0% |
Constrains crosslinker quantity |
| 14 |
Formulation is anhydrous and substantially free of volatile solvents after drying |
Adds drying/solvent character limitation |
| 15 |
Drug-containing releasing adhesive mixture recites more specific ranges and selections: C4–C12 alkyl acrylate 60–80% and hardening 15–30%, crosslink functional 1–20% (selected from claim list), crosslinker 0.005–2.0%, drug 3–35%, drug list limited |
This is a highly specified claim set and is likely closer to actual products |
| 16 |
Highly plasticizing drug is selegiline |
Mirrors claim 9 for the more specified claim 15 |
| 17 |
Formulation “does not include a solvent after drying” |
Tightens the solvent/drying feature similar to claim 14 |
When does US 7,070,808 lose exclusivity, and what are the practical end dates for filing/launch?
US patent term mechanics:
- A US utility patent like 7,070,808 typically expires 20 years from its earliest effective non-provisional filing date under 35 USC 154, subject to adjustments.
- Patent term extension (PTE) is possible only if tied to regulatory review and an eligible active ingredient, which requires verifying PTE applicability.
Because the earliest effective filing date, any patent term adjustment, and any PTE are not provided in the prompt, no exact expiration date can be stated from the information available.
(Per operating constraints, no partial/guess end-date is provided.)
Which generic entry risks exist for products using acrylic drug-containing adhesives that load selegiline or fluoxetine?
Infringement-critical parameters
Risk of infringement rises sharply when a candidate product matches all of:
- Acrylic adhesive base in the broad range (65–97% by weight)
- Polymer monomer blend ratios within the required windows
- Presence and selection of crosslinking functionality
- Use of an enumerated crosslinking agent (or a construed equivalent if “multivalent metals” captures it)
- “Highly plasticizing drug” is on the enumerated list (if litigated on dependent claim sets)
- Drug loading 3–35% (and potentially 3–18% or 3–25% depending on asserted dependents)
- Product is solvent-lean after drying if claim 14/17 are asserted
Common design-around levers
- Change the monomer ratios outside the required windows (especially within-adhesive C4–C12 and C1–C4 percentages)
- Use a different crosslinkable monomer identity or shift outside 1–20% (or 3–8% in a dependent range)
- Use different crosslinker species outside the enumerated titinates/aluminum salts/urea/melamine families
- Reduce drug loading below 3% or shift to >35% (depending on commercial formulation goals)
- Avoid solvent characteristics that map to the “substantially free” limitations after drying
What formulations are protected by US 7,070,808 (drug-in-adhesive vs method-of-use), and does it cover transdermal/patch formats?
Claim type: The claims are formulation claims: “therapeutic adhesive formulation” and “drug containing and releasing adhesive mixture.”
No method-of-use claim text is provided in the prompt, and no biologic mechanism language appears. The scope therefore centers on the composition of an adhesive matrix containing a drug.
Format coverage: The independent claim language does not explicitly require a patch, tape, or delivery system geometry. However, the term “adhesive” and “drug containing and releasing adhesive” maps strongly to transdermal or topical adhesive delivery systems.
What patent estate and related filings are likely tied to 7,070,808 (continuations, divisionals, or related formulations)?
Not determinable from provided information.
No application publication numbers, assignees, priority dates, or family members are provided, so the scope of the broader estate cannot be accurately reconstructed.
How does US 7,070,808 compare with other acrylic adhesive drug-load patents (selegiline, fluoxetine, and topical anesthetic actives)?
Not computable from provided information.
A comparative landscape requires citation-linked patents, inventor/assignee matches, or family members. None are provided.
Orange Book status and FDA pathway: what does US 7,070,808 cover for generics or 505(b)(2) vs ANDA?
Not determinable from provided information.
To map to Orange Book listings, one must know the associated NDA/ANDA product and active ingredient. The prompt does not provide the listed drug product, marketing authorization number, or Orange Book patent listing record for 7,070,808.
What is the litigation and settlement risk profile for US 7,070,808?
Not determinable from provided information.
A litigation profile requires dockets, parties, asserted patents, and claim constructions or settlement terms. None are provided.
Key claim-to-product matching checklist for infringement screening of a new adhesive drug system
Use the claim boundaries as a gating matrix:
A. Polymer composition
- Total acrylic adhesive: 65–97 wt%
- Within acrylic polymer:
- C4–C12 alkyl acrylate: 40–90 wt% (or 60–80 if matching dependent sets)
- C1–C4 hardening monomer: 10–40 wt% (or 15–30 in dependent set)
- Functionalizing monomer: 1–20 wt% (or 3–8 in dependent set)
B. Crosslinking system
- Crosslinker present: identity constrained if asserted under dependent claim 12
- Crosslinker amount: 0.005–2.0 wt% (dependent claim 13)
C. Drug inclusion
- Drug loading: 3–35 wt% (and narrower windows if dependents are asserted)
- Drug identity: match claim 8 list; selegiline-specific versions exist
D. Solvent and drying
- If asserted: “anhydrous and substantially free of volatile solvents after drying” and/or “does not include a solvent after drying” (claims 14 and 17)
Key Takeaways
- US Patent 7,070,808 is centered on composition-of-matter protection for acrylic adhesive drug delivery formulations containing a “highly plasticizing drug.”
- The strongest claim boundaries are the monomer ratio windows and the drug loading window (3–35 wt%), plus crosslinking functionality and agent constraints.
- Drug scope is limited to enumerated drugs in the dependent claims, with selegiline explicitly called out in dependent form.
- Exclusivity end dates, Orange Book status, and litigation risk cannot be concluded from the information provided.
- Infringement screening should focus on matching all quantitative ranges and the crosslinker/functional monomer selections, then check solvent/drying character if those dependent claims are asserted.
FAQs
-
Does US 7,070,808 require a specific delivery device such as a patch?
The claims provided cover an adhesive formulation/mixture. The text does not specify a patch, but it requires an adhesive that releases drug.
-
Can a formulation using selegiline avoid infringement by changing polymer monomer ratios?
Infringement depends on staying within (or outside) the required monomer percent windows and functionalizing monomer fraction; ratio shifts are a principal design-around lever.
-
If a different plasticizing drug is used, does the patent still apply?
Dependent claims enumerate specific drugs; Claim 1 uses “highly plasticizing drug,” which can create interpretive risk if the court construes the term broadly.
-
How important is the crosslinker amount in US 7,070,808?
Crosslinker amount is specified in dependent claim 13 (0.005–2.0%). If that dependent claim is asserted, amount becomes a direct infringement criterion.
-
What role do solvent and drying characteristics play?
Claims 14 and 17 add limits tied to being anhydrous and substantially free of volatile solvents after drying.
References
- US Patent 7,070,808 (claims as provided in prompt).
More… ↓
⤷ Start Trial
|
